Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and …
Over the last 12 months, insiders at Medtronic plc have bought $0 and sold $4.7M worth of Medtronic plc stock.
On average, over the past 5 years, insiders at Medtronic plc have bought $2.32M and sold $15.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,010 shares for transaction amount of $517,333 was made by ANDERSON RICHARD H (director) on 2021‑12‑16.
2024-06-07 | Sale | Chairman and CEO | 19,113 0.0015% | $83.77 | $1.6M | +4.84% | ||
2024-04-08 | Sale | EVP & President, Surgical OU | 854 <0.0001% | $83.14 | $71,002 | +1.36% | ||
2024-02-21 | Sale | EVP & President Cardiovascular | 30,695 0.0023% | $85.13 | $2.61M | -2.08% | ||
2023-12-19 | Sale | EVP & Pres Neuroscience | 4,997 0.0004% | $82.17 | $410,603 | +3.27% | ||
2023-08-23 | Sale | EVP Global Ops & Supply Chain | 10,000 0.0008% | $83.84 | $838,400 | -2.28% | ||
2023-08-14 | Sale | EVP & Pres Neuroscience | 1,000 <0.0001% | $83.38 | $83,380 | -1.82% | ||
2023-08-04 | Sale | EVP & President, Surgical OU | 1,352 0.0001% | $84.11 | $113,717 | -2.64% | ||
2023-07-14 | Sale | EVP & Pres Neuroscience | 2,000 0.0002% | $87.97 | $175,940 | -6.21% | ||
2023-07-10 | Sale | EVP and Pres. Global Regions | 5,514 0.0004% | $86.58 | $477,420 | -4.88% | ||
2022-12-13 | Sale | EVP & President Cardiovascular | 16,631 0.0013% | $80.50 | $1.34M | +3.72% | ||
2022-10-14 | Sale | EVP and Pres. Global Regions | 2,404 0.0002% | $81.54 | $196,015 | +2.51% | ||
2022-03-18 | Sale | EVP & Chief Financial Officer | 682 <0.0001% | $110.00 | $75,020 | -19.30% | ||
2022-03-11 | Sale | SVP, Chief HR Officer | 6,000 0.0005% | $105.30 | $631,800 | -14.10% | ||
2021-12-23 | Sale | EVP & Pres. Medical Surgical | 7,218 0.0005% | $102.04 | $736,525 | -8.14% | ||
2021-12-16 | director | 5,010 0.0004% | $103.26 | $517,333 | -6.07% | |||
2021-12-06 | Sale | EVP & Chief Financial Officer | 682 <0.0001% | $110.00 | $75,020 | -11.83% | ||
2021-09-30 | Sale | SVP General Counsel & Corp Sec | 49,147 0.0037% | $126.58 | $6.22M | -16.50% | ||
2021-08-31 | Sale | SVP General Counsel & Corp Sec | 50,775 0.0038% | $134.17 | $6.81M | -20.23% | ||
2021-08-25 | Sale | CEO | 10,100 0.0007% | $132.67 | $1.34M | -20.38% | ||
2021-08-25 | Sale | EVP & Pres Diabetes/Cardiovasc | 28,419 0.0021% | $134.08 | $3.81M | -20.38% |
ISHRAK OMAR | Executive Chairman | 561032 0.0437% | $86.21 | 2 | 7 | +5.04% |
ANDERSON RICHARD H | director | 108374 0.0085% | $86.21 | 6 | 0 | +0.88% |
POZEN ROBERT C | director | 60964 0.0048% | $86.21 | 1 | 1 | +11.75% |
Lenehan James T | director | 47028 0.0037% | $86.21 | 1 | 1 | +7.69% |
PARKHILL KAREN L | EVP & Chief Financial Officer | 34946 0.0027% | $86.21 | 1 | 6 | +19.19% |
The Vanguard Group | $11.01B | 9.85 | 126.28M | -0.21% | -$23.07M | 0.2 | |
BlackRock | $9.93B | 8.89 | 113.98M | -3.87% | -$400.24M | 0.22 | |
State Street | $5.28B | 4.68 | 60.07M | -1.39% | -$74.31M | 0.22 | |
JPMorgan Chase | $2.76B | 2.47 | 31.63M | +24.59% | +$543.97M | 0.25 | |
Capital Research Global Investors | $2.69B | 2.41 | 30.88M | +7.09% | +$178.14M | 0.61 |